Cancer

October 6, 2024

Role of natural products in tumor therapy from basic research and clinical perspectives

Announcing a new publication for Acta Materia Medica journal. Cancer is the leading cause of morbidity and mortality worldwide and...

New test detects more cases of cervical cancer

Researchers at Karolinska Institutet in Sweden and the University of Innsbruck in Austria have developed a simpler and more effective...

Images in a woman who had a BI-RADS density of 2.

AI detects more breast cancers with fewer false positives

OAK BROOK, Ill. – Using artificial intelligence (AI), breast radiologists in Denmark have improved breast cancer screening performance and reduced...

Scientists push single-molecule DNA sequencing to the next level

SAN FRANCISCO—June 4, 2024—In recent years, technologies that allow scientists to study a person’s DNA at single-molecule resolution have vastly...

Hypoxemia due to sleep apnea is associated with risk of lung cancer reoccurrence

DARIEN, IL – A new study to be presented at the SLEEP 2024 annual meeting is the first to find...

Two-pronged attack strategy boosts immunotherapy in preclinical studies

JUNE 3, 2024, NEW YORK – A novel immunotherapy approach developed by Ludwig Cancer Research scientists employs a two-pronged attack...

Sarcoma clinical trial funded by stand up to cancer reduces risk of relapse by 43%

LOS ANGELES – June 3, 2024 – For the last three decades, breakthroughs have been sparse for soft tissue sarcomas,...

UITM-CaixaResearch presents promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumors, especially in melanoma

Preliminary data from the first patient trial of the bispecific antibody FS222 indicate a manageable toxicity profile and promising...

Spanish-language content for lung cancer patients helps break down barriers to care

MIAMI, FLORIDA (June 3, 2024) – Estelamari Rodriguez, M.D., M.P.H., is the recipient of the Patient Educator of the Year...

Screening for prostate cancer with first-line MRI less cost-effective than first-line PSA testing